• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

EXPERT Q&A

Inside eCOA 

At Signant, our SmartSignals eCOA combines advanced technology with dedicated support from our clinical and digital health sciences teams, ensuring study success through solution, science, scale, and service pillars, as highlighted in our video series.

eCOA 4S:  Solution, Science, Scale, Service

At Signant , we understand that successful eCOA implementation requires four pillars: solution, science, scale, and service. Our SmartSignals eCOA is much more than innovative technology; it’s also access to our team of in-house clinical and digital health sciences experts who help study teams navigate common trial complexities. In this video series, our Digital Health Sciences Team answers frequently asked questions and offers best practices to ensure eCOA study success. 

EPISODE 1

How do we use PROs to monitor disease incidence alongside reactogenicity in vaccine trials? 

Greta Marie de Waal
Greta Marie De Waal, PhD
Clinical Scientist
Digital Health & eCOA Science
EPISODE DESCRIPTION
Episode 1 Description

How do we use PROs to monitor disease incidence alongside reactogenicity in vaccine trials?

Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participant follow up periods, multiphase designs, and critical data management needs. Our SmartSignals solution navigates these challenges via flexible implementation options, built-in alerts that keep PROs on track, and data management services. Greta Marie De Waal, science and medicine clinical scientist, provides insights from her experience on using PROs to monitor disease incidence alongside reactogenicity in vaccine trials.   

Greta Marie De Waal, PhD

Dr. de Waal provides scientific consultation to clients relating to the implementation of electronic clinical outcome assessments. Dr. de Waal has 2+ years’ experience in the clinical research industry, previously forming part of a Medical Strategy team. She has been supporting projects across a wide variety of therapeutic areas, including oncology, infectious disease, and dermatology.

EPISODE 2

When should a patient or an observer complete COA instrument in pediatric trials?

Branden Kusanto
Branden Kusanto, PhD
Clinical Scientist
Digital Health & eCOA Science 
EPISODE DESCRIPTION
Episode 2 Description

When should a patient or an observer complete COA instrument in pediatric trials?

Pediatric clinical trials come with unique challenges. Regarding COA selection, our scientists advise on when to use self-completion, proxy, and observer versions. Branden Kusanto, a clinical scientist focused on implementing eCOA best practices on clinical trials in multiple therapeutic areas, shares insights from his experience on completing COAs in pediatric trials.

EPISODE 3

How can we apply PROM subscales discretely to meet FDA draft guidance for PROs in Oncology trials? 

Viani Figueroa (2)
Dr. Viani Figueroa Vazquez 
Sr. Clinical Specialist

 

EPISODE DESCRIPTION
Episode 3 Description

How can we apply PROM subscales discretely to meet FDA draft guidance for PROs in Oncology trials? 

Considering the recent FDA draft guidance on PROs in oncology clinical trials, oncology PROM strategy may be well suited to a modular approach. The draft guidance recommends PROMs are selected to allow focused, independent measurement of five specific core domains: disease-related symptoms, symptomatic adverse events, the overall impact of side effects, physical function, and role function. Moreover, the frequency of administration of each core domain should vary – with physical function and adverse events identified as requiring more frequent assessment, especially during the early stages of treatment. Both the specificity and measurement frequency of these core domains lead us to consider the independent application of sub-scales within existing validated measures. Senior clinical specialist Viani Figueroa Vazquez provides insights on applying PROM subscales to meet FDA draft guidance for PROs in oncology trials. 

EPISODE 4

What are best practices in pain and pain management data capture? 

Lauren Crooks (1)
Laura Crooks
Clinical Specialist
EPISODE DESCRIPTION
Episode 4 Description

What are best practices in pain and pain management data capture? 

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often used as experimental treatments in these studies bring stricter drug accountability requirements. Pain patients also face debilitating symptoms that can make participation in studies difficult. Lauren Crooks, science and medicine clinical scientist, provides insights from her experience on the best practices in pain and pain management data capture. 

Roger Smith

Chief Executive Officer

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.